Can mycophenolate mofetil be tapered safely in myasthenia gravis? A retrospective, multicenter analysis
- 23 April 2015
- journal article
- research article
- Published by Wiley in Muscle & Nerve
- Vol. 52 (2) , 211-215
Abstract
Introduction: Mycophenolate mofetil (MMF) is frequently used to treat myasthenia gravis, but there is little information to guide clinicians on the safety of reducing the dose in well‐controlled patients. Methods: This retrospective chart review at 3 institutions identified 92 patients who had undergone MMF taper after achieving either pharmacologic remission or minimal manifestations status. Statistical analysis was performed to assess differences in patient characteristics between patients who had successfully tapered MMF and those who relapsed. Results: Of 92 patients undergoing a taper, 30 relapsed. The relapses were mild, transient, and usually responded to increased MMF dose. MG crisis did not occur. The mean dose at time of relapse was 888 mg/day. Patients with relapses were tapered more quickly (8.4 vs. 62.4 months). Conclusions: Tapering MMF appears safe after years of disease stability. Reducing the dose at a dose of only 500 mg/day every 12 months is recommended. Muscle Nerve 52: 211–215, 2015Keywords
This publication has 11 references indexed in Scilit:
- Myasthenia GravisSeminars in Neurology, 2012
- Mycophenolate mofetil in AChR‐antibody‐positive myasthenia gravis: Outcomes in 102 patientsMuscle & Nerve, 2010
- Progressive Multifocal Leukoencephalopathy and Use of Mycophenolate Mofetil After Kidney TransplantationTransplantation, 2008
- An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravisNeurology, 2008
- A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravisNeurology, 2008
- Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetilNeurology, 2005
- Mechanisms of action of mycophenolate mofetilLupus, 2005
- Mechanisms of action of mycophenolate mofetilLupus, 2005
- A randomized double‐blind trial of prednisolone alone or with azathioprine in myasthenia gravisNeurology, 1998
- A Clinical Therapeutic Trial of Cyclosporine in Myasthenia GravisaAnnals of the New York Academy of Sciences, 1993